4Goldie JH,Coldman AJ.A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate [J].Cancer Treat Rep,1979,63 (2):1727.
5Fisher B,Bryant J,Wolmark N,et al.Effect of preoperative chemotherapy on the outcome of women with operable breast cancer[J].Clin Oncol,1998,16(3) :2672.
6Ezzat AA,Rahal M,Ajarim D,et al.Dose-dense neoadjuvant sequential chemotherapy in the management of locally advanced breast cancer:a phase Ⅱ study [J].Pro Am Soc Clin Oncol,2003,22(4) :51.
7Milla A,Morales S,Burillo MA,et al.High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC):an ONCOPAZ and associated hospitals study[J].Breast Cancer Res Treat,2001,69(3) :271.
二级参考文献10
1Fisher B, Gunduz N, Coyle J, et al. Presence of a growth-stimulating factor in serum following primary tumor removal in mice. Cancer Res,1989,49:1996-2001.
2Goldie JH, Coldman AJ. A mathematical model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979,63:1727-1733.
3Fisher B,Bryant J,Wolmark N,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol,1998,16: 2672-2685.
4Gardin G, Rosso R, Campora E,et al. Locally advanced non-metastatic breast cancer: analysis of prognostic factors in 125 patients homogeneously treated with a combined modality approach. Eur J Cancer, 1995,31A: 1428-1433.
5Chen SC, Chang HK, Lin YC, et al. Neoadjuvant chemotherapy with biweekly epirubicin and paclitaxel for locally advanced breast cancer. Proc Am Soc Clin Oncol, 2003,22:58.
6Moliterni A, Tarenzi E, Capri G, et al. Pilot study of primary chemotherapy with doxeorubicin plus paclitaxel in women with locally advanced or operable breast cancer. Semin Oncol, 1997, 24(5 suppl 17): S17-10-S17-14.
7Ezzat AA, Rahal M, Ajarim D, et al. Dose-dense neoadjuvant sequential chemotherapy in the management of locally advanced breast cancer: a phase Ⅱ study. Pro Am Soc Clin Oncol, 2003,22:51.
8Milla A, Morales S, Burillo MA, et al. High-dose epirubicin plus docetaxel in locally advanced breast cancer (LABC): an ONCOPAZ and associated hospitals study. Breast Cancer Res Treat, 2001,69:271.
9Wachters B, Annemie P, Ines D, et al. Efficacy and tolerance of epirubicin docetaxel (E-T) in patients with inflammatory breast caner (IBC). Breast Cancer Res Treat, 2001,69:301.
10Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracyclinecontaining chemotherapy. J Clin Oncol, 1999, 17: 1413-1424.
